The Food and Drug Administration on Wednesday approved GlaxoSmithKline's vaccine against the respiratory syncytial virus, making it the first authorized RSV shot in the U.S.
Why it matters: GSK's vaccine is approved for adults aged 60 and older, a population that is particularly vulnerable to RSV. The disease causes up to 10,000 deaths and as many as 160,000 hospitalizations for people 65 and up per year, per the Centers for Disease Control and Prevention.
